DRI12544 (18+ years), QUEST (12+ years), VOYAGE (6-11 years)

The most common adverse reactions from the DUPIXENT asthma trials were injection site reactions,l oropharyngeal pain, and eosinophilia.m These adverse reactions occurred in ≥1% of patients receiving DUPIXENT + SOC and at a higher rate than in patients receiving placebo + SOC in DRI12544 and QUEST (6-month safety pool).1

The safety profile of DUPIXENT through Week 52 was similar to the safety profile from studies in adult and pediatric subjects 12 years of age and older with moderate-to-severe asthma with the addition of helminth infections.1

lInjection site reactions cluster includes erythema, edema, pruritus, pain, and inflammation.1

mNone met the criteria for serious eosinophilic conditions.1